PropertyValue
?:abstract
  • From the Document: This Fact Sheet informs you of the significant known and potential risks and benefits of the emergency use of the xMAP® SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2] Multi-Antigen IgG [Immunoglobulin G] Assay The xMAP® SARS-CoV-2 Multi-Antigen IgG Assay is authorized for the detection of IgG antibodies to SARS-CoV-2 in human serum and plasma COVID-19 (Disease);Health--Testing
?:creator
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Fact Sheet for Healthcare Providers: Luminex Corporation, xMAP® SARS-CoV-2 Multi-Antigen IgG Assay
?:type
?:who_covidence_id
  • #740844
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/0bqpevvo>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/0bqpevvo>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all